Browse Certification Practice Tests by Exam Family

Series 161: Research Communications Review

Try 10 focused Series 161 questions on Research Communications Review, with explanations, then continue with the full Securities Prep practice test.

Series 161 Research Communications Review questions help you isolate one part of the FINRA outline before returning to a mixed practice test. The questions below are original Securities Prep practice items aligned to this topic and are not copied from any exam sponsor.

Open the matching Securities Prep practice route for timed mocks, topic drills, progress tracking, explanations, and the full question bank.

Topic snapshot

ItemDetail
ExamFINRA Series 161
Official topicFunction 1 — Review and Approve Research Analysts’ Communications
Blueprint weighting68%
Questions on this page10

Sample questions

Question 1

A supervisory analyst is asked to approve a same-day rating change from Hold to Buy on ABC Biotech. The approval package includes the analyst’s Reg AC certification, current disclosures, and price-target support memo. The firm’s workflow note shows ABC Biotech was placed on a deal-related publication hold 3 days ago because the firm joined a follow-on offering syndicate. Firm policy states that no issuer-specific research may be published while that hold remains in effect unless Legal/Compliance documents a release. Which item is missing or deficient?

  • A. An issuer fact-check log signed by investor relations
  • B. A sales-force briefing note describing the recommendation change
  • C. A documented Legal/Compliance release from the publication hold before approval
  • D. A longer valuation appendix supporting the new price target

Best answer: C

Explanation: Because the issuer is in a restricted timing window, the decisive missing control is documented clearance lifting the publication hold before the rating change can be approved or disseminated.

The package is deficient because the issuer is still subject to a deal-related publication hold. Before a supervisory analyst can approve or allow dissemination of the rating change, the firm must have documented Legal/Compliance clearance lifting that hold under firm policy.

The core issue is not whether the recommendation is analytically supported; it is whether publication is permissible during a restricted timing window. Here, the firm’s own workflow shows an active deal-related publication hold, and the policy expressly prohibits issuer-specific research unless Legal/Compliance documents a release. That means the supervisory analyst’s first required step is to stop approval and obtain that clearance.

A sound supervisory review in this situation is:

  • verify the hold status in the firm’s restricted workflow
  • confirm whether a release has been granted
  • retain evidence of the release before approval or dissemination
  • withhold publication until that control is satisfied

Better analysis, issuer fact-checking, or internal sales preparation may be useful in other contexts, but none cures an active publication hold.

  • More analysis is secondary because stronger valuation support does not override an active publication restriction.
  • Issuer fact-check can be appropriate for accuracy review, but issuer sign-off is not the deciding control when the problem is a still-active hold.
  • Sales briefing concerns internal communication, not publication permissibility during the restricted window.

Question 2

Which statement is most accurate about the relevance of NYSE Rule 472 communication standards to a supervisory analyst’s approval decision?

  • A. A report with complete conflict disclosures still should not be approved if its language is exaggerated, promissory, or otherwise unbalanced.
  • B. If the issuer has reviewed the draft for factual accuracy, the supervisory analyst may treat content-balance concerns as satisfied.
  • C. NYSE Rule 472 standards matter only after publication, when sales personnel use the report with customers.
  • D. Once Regulation AC is included, NYSE Rule 472 no longer affects the supervisory analyst’s approval decision.

Best answer: A

Explanation: NYSE Rule 472 communication standards make content fairness and balance an approval issue, so disclosures do not cure exaggerated or misleading language.

NYSE Rule 472 is relevant at the approval stage because it addresses the content standards of research communications, not just post-publication conduct. A supervisory analyst must consider whether the report is fair, balanced, and free of exaggerated or promissory language even when required disclosures are present.

The core concept is that NYSE Rule 472 communication standards directly affect whether a supervisory analyst may approve a research communication for dissemination. The review is not limited to checking disclosure boxes; it also includes judging whether the communication is fair, balanced, and not misleading.

A supervisory analyst should verify that the report:

  • distinguishes fact from opinion
  • avoids exaggerated or promissory statements
  • presents risks and limitations in a balanced way
  • is suitable for dissemination under firm controls

That is why complete conflict disclosures or an analyst certification do not cure defective content. Likewise, issuer factual review does not replace the firm’s supervisory judgment about tone, balance, and compliance. The key takeaway is that communication standards are part of the approval decision itself, not a separate issue left to sales use or later monitoring.

  • Post-publication only fails because content standards apply before dissemination, when approval is being considered.
  • Issuer review reliance fails because issuer fact-checking does not satisfy the supervisory analyst’s duty to assess fairness and balance.
  • Reg AC replaces content review fails because certification and disclosure requirements do not eliminate separate communication-standard review.

Question 3

A supervisory analyst is asked to approve a same-day notice of a rating change on XYZ Corp. The firm’s investment banking department is a co-manager in XYZ’s follow-on common stock offering, and pricing is expected later this week. For purposes of deciding whether release is permissible under Regulation M, which fact is NOT necessary to confirm before release?

  • A. Whether the analyst used a discounted cash flow model
  • B. Whether the firm is a distribution participant
  • C. Whether the common stock qualifies for a publication exception
  • D. Whether the follow-on offering is still pending

Best answer: A

Explanation: Regulation M release permissibility turns on distribution status, security classification, and offering timing, not on the analyst’s valuation method.

Before approving release under Regulation M, the supervisory analyst must verify the firm’s role in the distribution, the type of security involved, and whether the offering is still active. The analyst’s modeling approach may matter for research quality review, but it does not decide the Regulation M publication question.

The key Regulation M gatekeeping issue is whether publication is restricted because the member is participating in a distribution of the issuer’s securities. That requires confirming three threshold facts: whether the firm is a distribution participant, whether the security falls within an applicable exception, and whether the offering is still pending so the restriction remains relevant. Those facts directly determine whether the communication can be released.

A valuation method such as discounted cash flow analysis may be relevant to reasonable-basis or content review, but it does not answer the Regulation M publication-timing question in this scenario. The core takeaway is to verify distribution role, security status, and offering status before dissemination.

  • Distribution role matters because publication restrictions apply based on whether the firm is participating in the distribution.
  • Security status matters because exceptions can depend on the type of security involved.
  • Offering status matters because timing determines whether the distribution-related restriction is still in effect.
  • Valuation method is a research-content issue, not the threshold Reg M release-control fact here.

Question 4

A supervisory analyst reviews a draft single-issuer research report. The report includes a $42 price target supported by disclosed assumptions and a bear/base/bull table. In the conclusion, the analyst adds: “If industry sentiment turns euphoric, the stock could easily trade above $80,” but the report provides no assumptions, probability, or analytical support for that figure. Before approving the report, what should the supervisory analyst do?

  • A. Permit the statement if the analyst sincerely believes the upside is achievable
  • B. Permit the statement if the report includes a general volatility disclosure
  • C. Require the $80 statement to be removed or recast as a labeled scenario with stated assumptions and support
  • D. Keep the statement but move it to the summary so readers see it as opinion

Best answer: C

Explanation: Unsupported upside language should not appear as research analysis unless it is grounded in disclosed assumptions and a reasonable analytical basis.

Research supervision requires fair and balanced communications with a reasonable basis for price targets and scenario analysis. An aspirational upside statement without disclosed assumptions or analytical support should be removed or rewritten into a clearly supported scenario before approval.

The key issue is whether the communication presents a supportable analytical scenario or merely promotional upside language. A supervisory analyst should not approve a statement such as a stock “could easily” reach a much higher level when the report gives no assumptions, no probability framework, and no evidence tying that figure to the analysis. If the firm wants to include additional upside cases, they should be clearly labeled as scenario analysis and supported by stated drivers such as revenue, margins, multiples, or other disclosed assumptions.

A general risk disclaimer does not cure unsupported optimism, and moving the sentence to another section does not change its lack of basis. The supervisory standard is substance over placement: opinions in research still need a reasonable basis and balanced presentation.

  • Generic disclosure fails because a broad volatility warning does not supply analytical support for the specific $80 claim.
  • Sincere belief fails because analyst conviction alone is not a substitute for stated assumptions and evidence.
  • Different placement fails because relocating the sentence does not transform unsupported upside into fair, balanced analysis.

Question 5

A supervisory analyst is reviewing a research report that upgrades XYZ Corp. to Buy. The report names a senior analyst and an associate analyst as jointly responsible for the recommendation and price target. In the approval file, the senior analyst has signed a Regulation AC certification. For the associate analyst, the file contains only the firm’s annual code-of-conduct attestation; there is no report-specific or otherwise retrievable Regulation AC certification. Restricted-list and Reg FD checks are complete. What is the primary compliance risk?

  • A. The file lacks a Regulation AC certification from each analyst primarily responsible for the report’s views.
  • B. The associate analyst’s total annual compensation has not been separately documented in the file.
  • C. Sales and trading have not been shown to receive the report at the same time.
  • D. The issuer did not approve the recommendation and price target before publication.

Best answer: A

Explanation: Regulation AC requires a compliant certification from each research analyst primarily responsible for the views expressed, and the annual conduct attestation does not satisfy that requirement.

The key red flag is the missing Regulation AC certification for the associate analyst who is jointly responsible for the recommendation and price target. A general annual attestation is not the required analyst certification and does not adequately document compliance for that report.

Regulation AC focuses on whether each research analyst primarily responsible for the views in a research report provides the required certification and whether the firm can evidence that certification. Here, the report identifies two analysts as jointly responsible for the recommendation and price target, but only one has a proper Reg AC certification in the file. The associate analyst’s annual code-of-conduct attestation is not a substitute because it is not the specific analyst certification tied to the report’s expressed views and compensation statement.

Before approval or dissemination, the supervisory analyst should verify that the missing analyst certification is obtained or otherwise properly documented in retained records. Questions about issuer sign-off, total annual compensation detail, or later distribution mechanics are not the blocking issue on these facts.

  • Annual pay detail fails because Reg AC is about certification of views and compensation tied to specific views, not documenting total yearly compensation.
  • Issuer approval fails because issuers do not need to approve a research recommendation or price target before publication.
  • Distribution timing fails because dissemination mechanics are secondary when the report cannot yet be approved due to missing certification evidence.

Question 6

A supervisory analyst is reviewing a company research report update on RedStone Energy for release this afternoon by email and posting on the firm’s client portal. The analyst’s draft and principal review are complete, but the disclosure block was copied from the prior report and states that the member and its affiliates do not beneficially own 1% or more of the issuer’s common equity. This morning, compliance notified the supervisory analyst that an affiliated fund crossed the 1% threshold last week and the disclosure text has not been revised. What is the best supervisory action?

  • A. Remove the rating and price target, then publish it as commentary.
  • B. Hold release, revise the disclosure, and approve the corrected report before dissemination.
  • C. Distribute it only to institutional clients while compliance reviews the issue.
  • D. Release the report now and send a corrected disclosure notice afterward.

Best answer: B

Explanation: The ownership disclosure is stale and misleading, so dissemination should be stopped until the corrected report receives final supervisory approval.

The disclosure is no longer accurate because an affiliate crossed the 1% ownership threshold before the report was disseminated. A supervisory analyst should stop release, ensure the conflict disclosure is corrected, and approve the final version before any distribution occurs.

The core issue is a stale and misleading conflict disclosure in a research report. Because compliance informed the firm before dissemination that an affiliate now beneficially owns more than 1% of the issuer’s common equity, the existing statement is inaccurate at the time of release. A supervisory analyst should not approve or allow dissemination of a report with a known disclosure defect.

The proper sequence is:

  • stop dissemination
  • update the disclosure to reflect current ownership
  • review the corrected version as the final report
  • release only after approval is complete

Sending a correction later is not the best action when the defect is known before publication. Changing the format or narrowing the audience does not eliminate the need for accurate conflict disclosure in the communication being distributed.

  • Post-publication fix fails because the disclosure problem was known before release, so the report should be held rather than corrected later.
  • Reclassify the piece fails because removing a rating and price target does not cure a false ownership disclosure in a company-specific communication.
  • Institutional-only distribution fails because limiting the audience does not excuse inaccurate or misleading conflict disclosure.

Question 7

A supervisory analyst is reviewing a premarket sector note that mentions Delta Air Holdings but makes no rating change. Firm policy states that if the firm is a distribution participant in an issuer’s offering, research may not be released until Compliance clears dissemination. Based on the exhibit, which action is best supported before the note is released?

Exhibit: Compliance release note

Issuer: Delta Air Holdings
Security discussed: Common stock
Offering: Follow-on common stock offering priced last night
Firm role: Selling group participation decision pending
Restricted list: Not yet activated
Release queue: 6:00 a.m. ET sector note
  • A. Hold release until the follow-on offering closes.
  • B. Require issuer approval before disseminating the note.
  • C. Approve release because no restricted list is active.
  • D. Confirm the firm’s selling-group decision before approving release.

Best answer: D

Explanation: The exhibit shows the offering and security type are known, but the firm’s distribution-participant status is still pending and must be confirmed first.

The key unresolved fact in the exhibit is the firm’s role in the follow-on offering. Because firm policy ties dissemination clearance to distribution-participant status, the supervisory analyst must confirm whether the firm will join the selling group before approving release.

This item turns on identifying the one material fact that is still unknown. The exhibit already tells you the security type and that a follow-on common stock offering has been priced. What remains unresolved is whether the firm will participate in the distribution as a selling group member. Under the stated firm policy, that role determines whether Compliance clearance is required before dissemination.

A supervisory analyst should not treat the lack of an active restricted list as enough by itself when the underlying participation decision is still pending. The correct supervisory step is to verify the firm’s distribution-participant status first, then follow the required release path. The closest trap is assuming current list status alone settles the issue, even though the key triggering fact has not yet been confirmed.

  • Restricted-list shortcut fails because the exhibit says the firm’s participation decision is still pending, so list status alone does not resolve release permissibility.
  • Automatic delay goes beyond the exhibit; nothing states every priced follow-on requires holding research until closing.
  • Issuer approval is not the missing control shown in the exhibit, which focuses on offering status and firm participation.

Question 8

A supervisory analyst reviews a company research report that follows the firm’s internal style guide, approved template, and disclosure order. However, the report calls the stock a “can’t miss winner,” emphasizes upside catalysts, and omits a discussion of material risks. What is the most appropriate supervisory conclusion before the report is disseminated?

  • A. Treat the report as a public appearance issue rather than a research report fairness issue.
  • B. Require revision before approval because external fairness standards still prohibit exaggerated and unbalanced research language.
  • C. Approve the report because compliance with the firm’s style guide satisfies communication standards if the template is approved.
  • D. Permit dissemination if the analyst later adds balancing risk comments in a sales meeting.

Best answer: B

Explanation: Internal formatting compliance does not cure a report that is not fair, balanced, and free of exaggerated or promissory claims.

The supervisory analyst should withhold approval and require revision. Under external communications and research standards, a report must be fair and balanced and cannot contain exaggerated or promissory language, even if it complies with internal formatting or style rules.

The core issue is that internal house style controls are not a substitute for external regulatory standards. A research report may use the correct template, disclosure sequence, and approved wording conventions yet still be unacceptable if its content is unfair, unbalanced, exaggerated, or promissory. Here, “can’t miss winner” is promotional language, and the omission of material risks makes the presentation one-sided.

A supervisory analyst’s job is to stop dissemination until the report is revised to meet external fairness standards applicable to research and communications. The right fix is content revision before approval, not relabeling the communication or trying to cure the problem later through an oral explanation. The key takeaway is that internal compliance is necessary but never sufficient when the substance fails fair-and-balanced standards.

  • The option relying on the firm’s style guide fails because internal approval architecture does not override external fair-and-balanced requirements.
  • The option treating this as a public appearance issue fails because the communication described is still a research report subject to research-content standards.
  • The option allowing later oral balancing comments fails because the report must be compliant before dissemination, not cured afterward.

Question 9

A supervisory analyst reviews two draft research updates. Standard firm disclosures and analyst certifications are complete for both.

  • Draft Alpha: “Alpha Energy has begun lender talks to extend debt maturities and preserve financial flexibility.” The analyst knows Alpha’s Form 8-K filed yesterday disclosed a covenant breach that allows lenders to accelerate repayment, but the draft omits that fact.
  • Draft Bravo: “Bravo Retail faces freight-cost pressure this quarter.” The draft also discusses a publicly disclosed warehouse fire and its expected effect on margins.

Which action best matches the supervisory analyst’s obligation before dissemination?

  • A. Revise both because every adverse fact must be included.
  • B. Revise only Draft Alpha before approval.
  • C. Revise only Draft Bravo before approval.
  • D. Approve both because neither draft is literally false.

Best answer: B

Explanation: A literally true statement can still be misleading if it omits a known adverse fact needed to put the discussion in proper context.

Research can be misleading by omission even when its statements are literally true. Draft Alpha’s discussion of lender talks and flexibility is incomplete without the known covenant breach, while Draft Bravo already includes the adverse event relevant to its margin discussion.

The key antifraud principle is that a research communication must not create a misleading overall impression through omission. A supervisory analyst is not limited to checking for outright false statements; the analyst must also ask whether a known adverse fact is necessary so the reader is not left with an unduly favorable view.

Here, Draft Alpha mentions lender talks and financial flexibility but leaves out the publicly disclosed covenant breach that gives lenders acceleration rights. That omitted fact changes the meaning of the lender discussion and makes the draft misleading unless revised. Draft Bravo does not raise the same issue because it includes the warehouse fire and its expected impact, so the negative development is already presented in context. Literal truth alone is not enough if the overall message is incomplete.

  • Literal truth only fails because antifraud review also covers misleading omissions, not just false statements.
  • Bravo revision fails because Bravo already discloses the adverse event tied to the operating impact discussed.
  • Include every bad fact is too broad; the test is whether omission makes the communication misleading, not whether all negatives are listed.

Question 10

A supervisory analyst reviews a draft company research report before publication. The analyst certification is complete, required conflict disclosures are included, and the issuer only verified factual statements. However, the report calls the stock a “must-own name,” says downside is “limited,” and emphasizes upside catalysts without comparable discussion of material risks. There is no evidence of pressure from investment banking, sales, trading, or the issuer. Before dissemination, what is the best next step?

  • A. Send the draft to legal only to confirm the issuer’s factual review was limited, then publish it
  • B. Escalate the draft as a research-independence breach and suspend coverage pending conflict review
  • C. Approve the report because certification and conflict disclosures are already complete
  • D. Return the draft for fair-balance revisions and re-review it before approval

Best answer: D

Explanation: The problem is primarily unbalanced, promotional content, so the report should be revised for fair balance before supervisory approval and dissemination.

This is primarily a Rule 2210 fair-balance problem, not a Rule 2241 independence problem. The report’s one-sided, promotional language and missing risk discussion must be corrected before the supervisory analyst can approve dissemination.

The core issue is that the communication is not fair and balanced. Describing a stock as a “must-own name,” minimizing downside, and highlighting positives without comparable risk discussion creates a content problem under communications standards. By contrast, Rule 2241 research-independence concerns usually involve improper influence, conflicts, or pressure from investment banking, sales, trading, or the issuer. The stem specifically removes those facts.

The proper sequence is:

  • send the draft back for balanced revisions
  • re-review the revised report for compliance
  • approve only after the content problem is fixed
  • then allow dissemination under normal controls

Conflict disclosures and analyst certification do not cure exaggerated or unbalanced statements. The closest distractor is the conflict-review escalation, but that would be the wrong primary route because no independence facts are present.

  • Conflict escalation is premature because the stem gives no sign of improper influence or other independence breakdown.
  • Immediate approval fails because disclosures and certification do not fix exaggerated, one-sided content.
  • Legal-only review misses the main problem; limited issuer fact-checking does not resolve the fair-balance deficiency.

Continue with full practice

Use the Series 161 Practice Test page for the full Securities Prep route, mixed-topic practice, timed mock exams, explanations, and web/mobile app access.

Free review resource

Use the Series 161 Cheat Sheet on SecuritiesMastery.com when you want a compact review before returning to the FINRA Series 161 Practice Test page.

Revised on Sunday, May 3, 2026